Immunoprecise Antibodies Stock Current Valuation
| IPA Stock | USD 0.41 0.03 7.89% |
Valuation analysis of Immunoprecise Antibodies helps investors to measure Immunoprecise Antibodies' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Immunoprecise Antibodies' Enterprise Value Over EBITDA is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.74, whereas Enterprise Value is forecasted to decline to about 271.4 K. Fundamental drivers impacting Immunoprecise Antibodies' valuation include:
Price Book 0.4671 | Enterprise Value 19.8 M | Enterprise Value Ebitda (4.68) | Price Sales 0.4571 | Enterprise Value Revenue 1.1428 |
Undervalued
Today
Please note that Immunoprecise Antibodies' price fluctuation is dangerous at this time. Calculation of the real value of Immunoprecise Antibodies is based on 3 months time horizon. Increasing Immunoprecise Antibodies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Immunoprecise Antibodies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immunoprecise Stock. However, Immunoprecise Antibodies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.41 | Real 2.3 | Target 7.99 | Hype 0.42 |
The real value of Immunoprecise Stock, also known as its intrinsic value, is the underlying worth of Immunoprecise Antibodies Company, which is reflected in its stock price. It is based on Immunoprecise Antibodies' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Immunoprecise Antibodies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Immunoprecise Antibodies helps investors to forecast how Immunoprecise stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immunoprecise Antibodies more accurately as focusing exclusively on Immunoprecise Antibodies' fundamentals will not take into account other important factors: Immunoprecise Antibodies Company Current Valuation Analysis
Immunoprecise Antibodies' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Immunoprecise Antibodies Current Valuation | 19.76 M |
Most of Immunoprecise Antibodies' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunoprecise Antibodies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Immunoprecise Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunoprecise Antibodies is extremely important. It helps to project a fair market value of Immunoprecise Stock properly, considering its historical fundamentals such as Current Valuation. Since Immunoprecise Antibodies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunoprecise Antibodies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunoprecise Antibodies' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Immunoprecise Antibodies has a Current Valuation of 19.76 M. This is 99.86% lower than that of the Biotechnology sector and 99.57% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.88% higher than that of the company.
Immunoprecise Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunoprecise Antibodies' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunoprecise Antibodies could also be used in its relative valuation, which is a method of valuing Immunoprecise Antibodies by comparing valuation metrics of similar companies.Immunoprecise Antibodies is currently under evaluation in current valuation category among its peers.
Immunoprecise Antibodies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunoprecise Antibodies from analyzing Immunoprecise Antibodies' financial statements. These drivers represent accounts that assess Immunoprecise Antibodies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunoprecise Antibodies' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 49.9M | 52.8M | 197.4M | 140.7M | 86.7M | 45.2M | |
| Enterprise Value | 47.3M | 54.7M | 159.1M | 113.3M | 85.6M | 55.4M |
Immunoprecise Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (1.15) % | ||||
| Operating Margin | (0.86) % | ||||
| Current Valuation | 19.76 M | ||||
| Shares Outstanding | 28.83 M | ||||
| Shares Owned By Insiders | 12.05 % | ||||
| Shares Owned By Institutions | 6.50 % | ||||
| Number Of Shares Shorted | 666.14 K | ||||
| Price To Book | 0.47 X | ||||
| Price To Sales | 0.46 X | ||||
| Revenue | 24.52 M | ||||
| Gross Profit | 11.56 M | ||||
| EBITDA | (22.95 M) | ||||
| Net Income | (27.18 M) | ||||
| Cash And Equivalents | 19.24 M | ||||
| Cash Per Share | 0.77 X | ||||
| Total Debt | 13.68 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.06 X | ||||
| Book Value Per Share | 1.20 X | ||||
| Cash Flow From Operations | (4.25 M) | ||||
| Short Ratio | 0.73 X | ||||
| Earnings Per Share | (0.77) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 72 | ||||
| Beta | 0.27 | ||||
| Market Capitalization | 11.01 M | ||||
| Total Asset | 59.99 M | ||||
| Retained Earnings | (100.27 M) | ||||
| Working Capital | 3.36 M | ||||
| Net Asset | 59.99 M |
About Immunoprecise Antibodies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunoprecise Antibodies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunoprecise Antibodies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunoprecise Antibodies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:Check out Immunoprecise Antibodies Piotroski F Score and Immunoprecise Antibodies Altman Z Score analysis. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 0.921 | Quarterly Revenue Growth (0.07) | Return On Assets (0.13) | Return On Equity (0.64) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.